If 340B drug discounts represent a significant share of your revenues, you won’t want to miss this webinar.

The integrity of the 340B drug discount program is under a microscope. Covered entities must act now to demonstrate that they are good program stewards and be prepared for additional reporting requirements.

As a bipartisan group of U.S. senators reviews responses to a congressional RFI seeking input on how to improve the 340B program, Sectyr is launching an informative webinar series designed to shed light on one of the group’s most pressing questions: How to improve the accountability of the 340B program and give policymakers and industry stakeholders greater confidence in its oversight.

On October 24, join Bill von Oehsen, Principal, Powers Pyles Sutter & Verville PC, and Craig Frost, President and COO of Sectyr, as we continue our discussion on these issues and how to ensure continuous 340B program compliance.

In Part 1 of the series we discussed an update on new reporting requirements and the continuous program compliance imperative.

Topics to be addressed, in Part 2, include:

• How has the job of managing 340B compliance changed over time?
• How might federal and state legislative and policy changes impact compliance management?
• Where does responsibility for 340B compliance truly lie?
• What tools are available to help manage 340B compliance?
• How does continuous program compliance differ from what we’re doing today?


This webinar is limited to 340B covered entities and 340B service companies.

This webinar is a master class on maximizing your claims capture and finally putting an end to falling short of your capture rate goals. We will use our collective experience working with multiple covered entities to demonstrate how PharmaForce has applied its logic-based system to close legacy gaps and double their capture rates — for some, upward of 40% over a few short weeks. Learn more about the five factors that changed the calculus for these clients and how we can do the same for you. And find what you’ve been missing.

In this installment of Verity's webinar series for 340B covered entities, we bring together guest speakers Jason Reddish and Ted Slafsky to discuss Medicare drug negotiation and its potential impact on the 340B program. Jason will cover beneficiary improvements, drug price negotiation, compliance considerations, and the effects of inflation penalties. Ted will provide the historical and political context of this new law, address lawsuits against the government to prevent drug price negotiation, and other insights. Jason Reddish is a Principal at the Washington, DC, law firm Powers Pyles Sutter & Verville, where he focuses on the 340B program and safety net pharmacy issues. Jason has extensive experience negotiating 340B-related agreements involving covered entities, contract pharmacies, administrators, payers, and others. He also works with covered entities to develop compliant policies and procedures and to audit current operations. Ted Slafsky is one of the nation’s leading experts on healthcare policy, pharmaceutical pricing, the hospital industry, and healthcare access. Based in Washington, D.C., he is the Publisher and CEO of 340B Report, the only news and intelligence service covering the 340B program. He is also Founder and Principal of the consulting firm Wexford Solutions.